Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02088203 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
A Phase 1 study of Diabetes Prevention, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02088203 is a Phase 1 study of Diabetes Prevention that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02088203, a Phase 1 study of Diabetes Prevention, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Dose 1
- DIETARY_SUPPLEMENT Dose 2
- DIETARY_SUPPLEMENT Dose 0
- DIETARY_SUPPLEMENT Dose 3
- DIETARY_SUPPLEMENT Dose 4
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-02 |
| Est. Completion | 2018-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02088203
The ClinicalTrials.gov registry entry for NCT02088203 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pennington Biomedical Research Center, which has 258 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Prevention appearing as the primary indexed condition, and to 5 interventions - of which Dose 1 is the first listed.
NCT02088203 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT02088203 about?
NCT02088203 is a clinical study titled "Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)". Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.
What is the current status of trial NCT02088203?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2014-02. Estimated completion is 2018-05.
What conditions does trial NCT02088203 study?
This clinical trial studies the following conditions: Diabetes Prevention.
What interventions are being tested in trial NCT02088203?
The interventions under investigation include: Dose 1 (DIETARY_SUPPLEMENT), Dose 2 (DIETARY_SUPPLEMENT), Dose 0 (DIETARY_SUPPLEMENT), Dose 3 (DIETARY_SUPPLEMENT), Dose 4 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02088203?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02088203 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Prevention
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.